Accueil>>Signaling Pathways>> Membrane Transporter/Ion Channel>> HCN Channel>>DK-AH 269

DK-AH 269 (Synonyms: Cilobradine)

Catalog No.GC18503

La cilobradine est un bloqueur des canaux HCN ; un bloqueur de canal ouvert des canaux Ih neuronaux et des canaux If cardiaques associés.

Products are for research use only. Not for human use. We do not sell to patients.

DK-AH 269 Chemical Structure

Cas No.: 186097-54-1

Taille Prix Stock Qté
1mg
37,00 $US
En stock
5mg
159,00 $US
En stock
10mg
297,00 $US
En stock
25mg
696,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

DK-AH 269 (Cilobradine) is an HCN Channel blocker; an open channel blocker of neuronal Ih and related cardiac If channels.
Target: HCN Channel blocker
DK-AH 269 is a HCN channel blocker that is about 3 times more potent than ZD7288. At a concentration of 10 μM, DK-AH 269 inhibits WT mHCN2 channel current by 86 ± 2% (n = 5). In contrast, I432A and A425G channel currents were only reduced by 14 ± 1% (n = 4) and 19 ± 2% (n = 8), respectively, by this concentration of DK-AH 269. The double mutant (I432A/A425G) channel was even less sensitive to 10 μM DK-AH 269 (8 ± 2% inhibition; n = 4).

References
[1]. Cheng L, et al. Molecular mapping of the binding site for a blocker of hyperpolarization-activated, cyclic nucleotide-modulated pacemaker channels. J Pharmacol Exp Ther. 2007 Sep;322(3):931-939.

Avis

Review for DK-AH 269

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DK-AH 269

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.